Navigation Links
Maxygen to Host Fourth Quarter and Year End 2007 Financial Results Conference Call on February 12, 2008
Date:1/29/2008

REDWOOD CITY, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, will host a conference call to discuss the company's fourth quarter and year end 2007 financial results at 11:30 a.m. ET (8:30 a.m. PT) on Tuesday, February 12, 2008. Russell Howard, Maxygen's chief executive officer, will host the call. A press release announcing Maxygen's fourth quarter and 2007 financial results will be issued that same day at approximately 9:00 a.m. ET.

The call will include discussion of non-GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most directly applicable GAAP measures can be found in the press release announcing Maxygen's fourth quarter and 2007 financial results. This press release will be available February 12, 2008 on Maxygen's website at http://www.maxygen.com/news.php.

Participants in the U.S. can access the call by dialing 866.825.3209 and using the passcode 31366535. International participants can dial 617.213.8061 and use the same passcode. A live webcast of the conference call will be available at http://www.maxygen.com/webcasts.

A telephone replay of the conference call will be available until March 12, 2008. To access the replay, please call 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 60709469. An archived version of the webcast will be available until March 12, 2008 at http://www.maxygen.com/webcasts.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Our lead program, MAXY-G34, is designed to be an improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor VIIa for the treatment of hemophilia. Maxygen's approach to drug discovery and development may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com


'/>"/>
SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. One-fourth of HIV patients believe their doctors stigmatize them
2. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
3. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
4. Hillenbrand Industries Announces Fourth Quarter 2007 Dividend
5. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
6. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
7. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
8. Health Insurance Premium Growth Slows for Fourth Straight Year
9. Dynatronics Announces Strong Fourth Quarter Profit
10. inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes
11. BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted to treat ... which is meant to relieve gout and pain caused by varicose veins. I drank ... every time. It relieved what VA doctors called the worst sinusitis case they'd seen ...
(Date:12/9/2016)... ... 2016 , ... An inventor from Cana, Va., wanted to fulfill the need ... park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates discrimination. ... set up in a matter of minutes, or even seconds. The SAFETY STRAP FOR ...
(Date:12/9/2016)... ... 2016 , ... MEDI+SIGN®, a provider of fully-automated patient monitoring ... for Emergency Departments (ED) has been added to their portfolio. Housed in a ... and with a simplified pallet of information available to the patient, the Digital ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... become Quality Insights beginning January 1, 2017. The name change aligns the ... to measuring and improving health care quality. , “We are very proud of ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Company LLC, announced the first national #QuackGivesBack campaign which supported local breast ... was our first franchise-wide Quack Gives Back initiative, and we’re very ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
(Date:12/8/2016)... December 8, 2016 Information products and services ... in Scopus , the world,s largest abstract and citation ... comprehensive metrics for journals from over 5,000 publishers. The new set ... to subscribe to and when to adjust a journal,s editorial strategy. ... , , ...
Breaking Medicine Technology: